AstraZeneca has successfully completed its acquisition of Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition.   The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy.   GC012F is ...